Last edition
News about "Paul Chaplin"
EC Approves Bavarian Nordic's Mpox Vaccine for Children
European Commission (EC) approves Bavarian Nordic's MVA-BN mpox/smallpox vaccine for children aged 2-11 years, expanding protection against mpox, smallpox and vaccinia.
Paul Chaplin | 07/08/2026 | By News Bureau
Serum Institute and Bavarian Nordic Expand Partnership for Chikungunya Vaccine Manufacturing
Bavarian Nordic and Serum Institute of India have expanded their strategic partnership through a chikungunya vaccine manufacturing agreement, enabling full technology transfer and supporting future supply to low- and middle-income countries while opening opportunities for further co-development.
Paul Chaplin | 11/03/2026 | By News Bureau | 216
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy